SMAC Mimetic Birinapant plus Radiation Eradicates Human Head and Neck Cancers with Genomic Amplifications of Cell Death Genes FADD and BIRC2

Cancer Res. 2016 Sep 15;76(18):5442-5454. doi: 10.1158/0008-5472.CAN-15-3317. Epub 2016 Jul 28.

Abstract

Comparison of tumors from The Cancer Genome Atlas (TCGA) reveals that head and neck squamous cell carcinomas (HNSCC) harbor the most frequent genomic amplifications of Fas-associated death domain (FADD), with or without Baculovirus inhibitor of apoptosis repeat containing BIRC2 (cIAP1), affecting about 30% of patients in association with worse prognosis. Here, we identified HNSCC cell lines harboring FADD/BIRC2 amplifications and overexpression by exome sequencing, RT-PCR, and Western blotting. In vitro, FADD or BIRC2 siRNA knockdown inhibited HNSCC displaying amplification and increased expression of these genes, supporting their functional importance in promoting proliferation. Birinapant, a novel SMAC mimetic, sensitized multiple HNSCC lines to cell death by agonists TNFα or TRAIL and inhibited cIAP1>XIAP>IAP2. Combination of birinapant and TNFα induced sub-G0 DNA fragmentation in sensitive lines and birinapant alone also induced significant G2-M cell-cycle arrest and cell death in UM-SCC-46 cells. Gene transfer and expression of FADD sensitized resistant UM-SCC-38 cells lacking FADD amplification to birinapant and TNFα, supporting a role for FADD in sensitization to IAP inhibitor and death ligands. HNSCC varied in mechanisms of cell death, as indicated by reversal by inhibitors or protein markers of caspase-dependent apoptosis and/or RIPK1/MLKL-mediated necroptosis. In vivo, birinapant inhibited tumor growth and enhanced radiation-induced TNFα, tumor responses, and host survival in UM-SCC-46 and -11B xenograft models displaying amplification and overexpression of FADD+/- BIRC2 These findings suggest that combination of SMAC mimetics such as birinapant plus radiation may be particularly active in HNSCC, which harbor frequent FADD/BIRC2 genomic alterations. Cancer Res; 76(18); 5442-54. ©2016 AACR.

MeSH terms

  • Animals
  • Antineoplastic Agents / administration & dosage*
  • Blotting, Western
  • Carcinoma, Squamous Cell / genetics*
  • Carcinoma, Squamous Cell / pathology
  • Cell Line, Tumor
  • Chemoradiotherapy / methods*
  • Dipeptides / administration & dosage*
  • Fas-Associated Death Domain Protein / genetics*
  • Female
  • Gene Amplification
  • Gene Knockdown Techniques
  • Head and Neck Neoplasms / genetics*
  • Head and Neck Neoplasms / pathology
  • Humans
  • Immunohistochemistry
  • Indoles / administration & dosage*
  • Inhibitor of Apoptosis Proteins / genetics*
  • Mice
  • Mice, Inbred BALB C
  • Mice, SCID
  • Real-Time Polymerase Chain Reaction
  • Squamous Cell Carcinoma of Head and Neck
  • TNF-Related Apoptosis-Inducing Ligand / administration & dosage
  • Tumor Necrosis Factor-alpha / administration & dosage
  • Ubiquitin-Protein Ligases / genetics*
  • Xenograft Model Antitumor Assays

Substances

  • Antineoplastic Agents
  • Dipeptides
  • FADD protein, human
  • Fas-Associated Death Domain Protein
  • Indoles
  • Inhibitor of Apoptosis Proteins
  • TNF-Related Apoptosis-Inducing Ligand
  • Tumor Necrosis Factor-alpha
  • birinapant
  • BIRC2 protein, human
  • Ubiquitin-Protein Ligases